Lumbosacral Radicular Pain Market Report 2026

The lumbosacral radicular pain market size has grown strongly in recent years. It will grow from $0.97 billion in 2025 to $1.02 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to aging population, spinal degenerative disorders, opioid-based pain management, hospital pain clinics, orthopedic surgery volumes.

The lumbosacral radicular pain market size is expected to see strong growth in the next few years. It will grow to $1.28 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to non-opioid pain therapy adoption, outpatient pain procedures, digital pain monitoring tools, minimally invasive spine technologies, rehabilitation program expansion. Major trends in the forecast period include rising use of multimodal pain management, growth of interventional spine procedures, increased demand for non-opioid therapies, expansion of rehabilitation-based care, adoption of minimally invasive pain treatments.

The increasing prevalence of degenerative spinal conditions is expected to drive growth in the lumbosacral radicular pain market in the coming years. Degenerative spinal conditions are disorders caused by the gradual wear and tear of the spine over time. Their rise is attributed to aging populations and lifestyle factors that increase spinal stress and nerve compression, creating greater demand for diagnosis and treatment. Lumbosacral radicular pain signals nerve root irritation or compression, helping clinicians identify underlying degenerative spinal conditions and guide effective management. For example, in May 2023, according to the University of Sydney, an Australia-based public university, it is projected that more than 800 million people worldwide will experience back discomfort by 2050. Therefore, the growing prevalence of degenerative spinal conditions is driving the lumbosacral radicular pain market.

The rising prevalence of obesity is also expected to propel growth in the lumbosacral radicular pain market. Obesity is a medical condition defined by excessive body fat accumulation, typically a body mass index (BMI) of 30 or higher, which increases the risk of multiple health complications. The increase in obesity is driven by sedentary lifestyles and widespread consumption of high-calorie, nutrient-poor foods, as modern work environments often involve prolonged sitting and limited physical activity. Excess body weight places additional mechanical stress on the lumbar spine, contributing to nerve compression and inflammation, which increases the incidence of lower back and leg pain. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity from 2023 to 2024, up from 64% in 2022 to 2023. Therefore, the rising prevalence of obesity is driving the lumbosacral radicular pain market.

In October 2024, Stryker Corporation, a US-based medical technology company, acquired Vertos Medical Inc. for an undisclosed amount. Through this acquisition, Stryker aims to strengthen its minimally invasive spine treatment portfolio by integrating Vertos Medical’s innovative technologies, improving patient outcomes, and expanding its leadership in the spinal health market. Vertos Medical Inc. is a US-based company specializing in minimally invasive treatments for lumbar spinal stenosis (LSS).

Major companies operating in the lumbosacral radicular pain market are Medtronic plc, Boston Scientific Corporation, Nevro Corp., SPR Therapeutics, Saluda Medical Pty Ltd., Nalu Medical Inc., Abbott Neuromodulation, Stryker Corporation, Zimmer Biomet Holdings Inc., Globus Medical Inc., NuVasive Inc., Orthofix Medical Inc., B. Braun Melsungen AG, Teleflex Incorporated, Merit Medical Systems Inc., Avanos Medical Inc., Halyard Health Inc., Terumo Corporation, Baxter International Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Pfizer CentreOne, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Lupin Limited, Zydus Lifesciences Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals Inc., Perrigo Company plc.

North America was the largest region in the lumbosacral radicular pain market in 2025. The regions covered in the lumbosacral radicular pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lumbosacral radicular pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the lumbosacral radicular pain market by affecting imports of pain management drugs, injection devices, implantable stimulators, and rehabilitation equipment. Interventional procedures and pharmacological treatments are most impacted, particularly in North America and Europe due to reliance on imported medical devices and specialty drugs. Hospitals, rehabilitation centers, and specialty clinics face higher operational expenses. Positively, tariffs are supporting local manufacturing of pain management devices and injectable pharmaceuticals.

The lumbosacral radicular pain market research report is one of a series of new reports that provides lumbosacral radicular pain market statistics, including lumbosacral radicular pain industry global market size, regional shares, competitors with a lumbosacral radicular pain market share, detailed lumbosacral radicular pain market segments, market trends and opportunities, and any further data you may need to thrive in the lumbosacral radicular pain industry. This lumbosacral radicular pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lumbosacral radicular pain is pain originating in the lower spine (lumbar and sacral regions) that radiates along a spinal nerve into the leg. It is commonly caused by nerve root compression or irritation, often resulting from conditions such as a herniated disc or spinal stenosis.

The main treatments for lumbosacral radicular pain include pharmacological therapies, non-pharmacological therapies, and interventional procedures. Pharmacological treatments involve the use of medications to diagnose, treat, or prevent medical conditions. Administration routes include oral, topical, injectable, and implantable methods. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, specialty clinics, rehabilitation centers, and homecare settings.

The lumbosacral radicular pain market includes revenues earned by entities by providing services such as non-surgical treatment services, interventional pain management services, and rehabilitation and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.